Becton Dickinson and Company (BDX) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public…
Total Cash From Operating Activities Chart for Becton Dickinson and Company
Becton Dickinson and Company (BDX) operating cash flow for FY2025 was USD 3.4B, a -9.7% change from FY2024. Becton Dickinson and Company's operating cash flow grew from USD 146.9M in 1989 to USD 3.4B in 2025 (2234.9% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -0.6%, 10-year CAGR of 7.1%, 20-year CAGR of 5.3%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $49.96B
- Implied Share Price
- $183.40
- Enterprise Value
- $66.05B
- Revenue (TTM)
- $22.48B
- EBITDA
- $6.12B
- Profit Margin
- 4.19%
- Trailing P/E
- 31.73
- Forward P/E
- 13.79
- Price/Book (MRQ)
- 2.05
- Price/Sales (TTM)
- 2.22
- EV/EBITDA
- 13.42
- EV/Revenue
- 2.94
- Dividend Yield
- 2.30%
- Book Value
- $89.64
- Free Cash Flow (FY2025)
- $2.67B
- Free Cash Flow Yield
- 5.34%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.